Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics

Chen, Mengyu; Lei, Ningjing; Tian, Wanjia; Li, Yong; Chang, Lei

doi:10.1177/17588359221118010

Cited by 14 publications

(15 citation statements)

References 202 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accumulating evidence indicates that some lncRNA play very active roles in OC progression, chemoresistance and recurrence through different molecular mechanisms (27)(28)(29). For example, LncRNA PVT1 regulated the transforming growth factor-β (TGF-β) pathway to promote ovarian cancer progression through sponging miR-148a-3p (30).…”

Section: Discussionmentioning

confidence: 99%

“…The united evaluation of plasma lncRNA ROR and CA125 has a higher diagnostic value for ovarian cancer than the detection of lncRNA ROR or CA125 alone ( 26 ). Accumulating evidence indicates that some lncRNA play very active roles in OC progression, chemoresistance and recurrence through different molecular mechanisms ( 27 - 29 ). For example, LncRNA PVT1 regulated the transforming growth factor-β (TGF-β) pathway to promote ovarian cancer progression through sponging miR-148a-3p ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The downregulation of LINC00273 inhibits the proliferation, invasion, and migration of ovarian cancer cells in vivo and in vitro

Shu¹,

Liu²,

Xue³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: This study sought to analyze long non-coding ribonucleic acid (lncRNA) LINC00273 expression in ovarian cancer tissues, and to preliminarily explore its effect on the growth and invasion of ovarian cancer cells and its influencing mechanism. Methods: Quantitative real-time polymerase chain reaction was performed to detect the LINC00273 expression levels of cancerous ovarian tissues and their related cell lines. The ovarian cancer cells with the highest expression of LINC00273 were transfected with a knockdown lentiviral vector targeting the LINC00273 sequence and a negative control plasmid. The effects of the LINC00273 knockdown on the invasion and growth of these cancerous cells were evaluated by clonogenic assays, flow cytometry, EdU(5-Ethynyl-2'-deoxyuridine), Cell Counting Kit-8, and Transwell assays. Western Blot was used to measure the LINC00273 knockdown effects on invasion and migration-related gene expression, and the knockdown effects on the ovarian proliferation ability of the cancer cells in vivo were analyzed by in vivo nude mouse experiments.Results: LINC00273 expression was significantly more increased in the cancerous ovarian tissues than the adjacent tissues. The LINC00273 expression of the ovarian cancer cell lines was higher than that of the normal ovarian epithelial cells. LINC00273 knockdown greatly suppressed the proliferative and clonogenic function of these cancerous cells. The flow cytometry results revealed that LINC00273 knockdown notably induced G0/G1 phase arrest in the ovarian cancer cells. LINC00273 knockdown also promoted E-cadherin expression in the ovarian cancer cells, and inhibited vimentin, matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and N-cadherin, expression to inhibit the invasion and migration ability of the ovarian cancer cells. The in vivo experiments indicated that LINC00273 knockdown suppressed in vivo cancer cell proliferation in the ovaries.Conclusions: LINC00273 is highly expressed in both ovarian cancerous tissues and ovarian cancerous cell lines. LINC00273 knockdown greatly suppressed the proliferative and invasive capabilities of the cancerous ovarian cells. In terms of the molecular process, it may be that the knockdown of LINC00273 promotes E-cadherin and inhibits vimentin, N-cadherin, MMP-2, and MMP-9 expression in cancerous ovarian cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The downregulation of LINC00273 inhibits the proliferation, invasion, and migration of ovarian cancer cells in vivo and in vitro

Shu¹,

Liu²,

Xue³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer (OC) is a major cause of lethality related to gynecological tumors with 295,000 new cases and 185,000 deaths annually worldwide ( 25 ). Thus, non-coding RNAs emerge not only as novel promising biomarkers for OC prognosis but also as therapeutic targets to prevent OC metastasis and inevitably chemoresistance, which is coupled to tumor recurrence and poor outcome of OC patients ( 26 ). Based on available human cancer datasets, higher cancer susceptibility candidate 15 ( CASC15 ) expression correlated with the poor prognosis of OC patients ( 27 ).…”

Section: Ovarian Cancermentioning

confidence: 99%

Unboxing the network among long non-coding RNAs and TGF-β signaling in cancer

Rodrigues-Junior,

Moustakas

2024

ujms

View full text Add to dashboard Cite

Deeper analysis of molecular mechanisms arising in tumor cells is an unmet need to provide new diagnostic and therapeutic strategies to prevent and treat tumors. The transforming growth factor β (TGF-β) signaling has been steadily featured in tumor biology and linked to poor prognosis of cancer patients. One pro-tumorigenic mechanism induced by TGF-β is the epithelial-to-mesenchymal transition (EMT), which can initiate cancer dissemination, enrich the tumor stem cell population, and increase chemoresistance. TGF-β signals via SMAD proteins, ubiquitin ligases, and protein kinases and modulates the expression of protein-coding and non-coding RNA genes, including those encoding larger than 500 nt transcripts, defined as long non-coding RNAs (lncRNAs). Several reports have shown lncRNAs regulating malignant phenotypes by directly affecting epigenetic processes, transcription, and post-transcriptional regulation. Thus, this review aims to update and summarize the impact of TGF-β signaling on the expression of lncRNAs and the function of such lncRNAs as regulators of TGF-β signaling, and how these networks might impact specific hallmarks of cancer.

show abstract

“…The CA125 antigen is one of the most extensively researched markers employed in ovarian cancer diagnosis. However, its use in clinical practice faces controversies resulting from the sensitivity and specificity of the test [7]. While its applicability in earlystage screening for ovarian cancer is uncertain, it is utilized as an indicator to appraise chemotherapy effectiveness and assess prognosis [8,9].…”

Section: Diagnostic Utility Of the Ca125 Testmentioning

confidence: 99%

Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer

Englisz,

Smycz-Kubańska,

Mielczarek-Palacz

2024

Diagnostics

View full text Add to dashboard Cite

One of the greatest challenges in modern gynecological oncology is ovarian cancer. Despite the numerous studies currently being conducted, it is still sometimes detected at late clinical stages, where the prognosis is unfavorable. One significant contributing factor is the absence of sensitive and specific parameters that could aid in early diagnosis. An ideal screening test, in view of the low incidence of ovarian cancer, should have a sensitivity of greater than 75% and a specificity of at least 99.6%. To enhance sensitivity and specificity, diagnostic panels are being created by combining individual markers. The drive to develop better screening tests for ovarian cancer focuses on modern diagnostic methods based on molecular testing, which in turn aims to find increasingly effective biomarkers. Currently, researchers’ efforts are focused on the search for a complementary parameter to those most commonly used that would satisfactorily enhance the sensitivity and specificity of assays. Several biomarkers, including microRNA molecules, autoantibodies, cDNA, adipocytokines, and galectins, are currently being investigated by researchers. This article reviews recent studies comparing the sensitivity and specificity of selected parameters used alone and in combination to increase detection of ovarian cancer at an early stage.

show abstract

Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics

Cited by 14 publications

References 202 publications

The downregulation of LINC00273 inhibits the proliferation, invasion, and migration of ovarian cancer cells in vivo and in vitro

The downregulation of LINC00273 inhibits the proliferation, invasion, and migration of ovarian cancer cells in vivo and in vitro

Unboxing the network among long non-coding RNAs and TGF-β signaling in cancer

Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer

Contact Info

Product

Resources

About